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Abstract
Background: Understanding the occurrence of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)-like
symptoms in a large non-hospitalized population, when the epidemic peak was occurring in Italy, is of paramount importance but
data are scarce.
Objective: Aims of this study were to evaluate the association of self-reported symptoms with SARS-CoV-2 nasopharyngeal
swab (NPS) test in non-hospitalized individuals and to estimate the occurrence of COVID-19-like symptoms in a larger non-
tested population.
Methods: This is an Italian countrywide self-administered cross-sectional web-based survey on voluntary adults who completed
an anonymous questionnaire in the period 13-21 April 2020. The associations between symptoms potentially related to SARS-
CoV-2 infection and NPS results were calculated as adjusted odds ratios with 95% confidence intervals (aOR, 95%CI) by means
of multiple logistic regression analysis controlling for age, sex, education, smoking habits, and the number of co-morbidities.
Thereafter, for each symptom and for their combination, we calculated sensitivity, specificity, accuracy and AUC in a ROC
analysis to estimate the occurrence of COVID-19-like infections in the non-tested population.
Results: A total of 171,310 responded to the survey (59.9% females, mean age 47.4 years). Out of the 4,785 respondents with
known NPS test result, 4,392 were not hospitalized. Among them, the NPS positive respondents (n=856) most frequently
reported myalgia (61.6%), olfactory and/or taste disorders (OTDs, 59.2%), cough (54.4%), and fever (51.9%) whereas 7.7%
were asymptomatic. Multiple regression analysis showed that OTDs (aOR 10.3, [95%CI 8.4-12.7]), fever (2.5, 95%CI 2.0-3.1),
myalgia (1.5, 95%CI 1.2-1.8), and cough (1.3, 95%CI 1.0-1.6) were associated with NPS positivity. Having two to four of these
symptoms increased the aOR from 7.4 (95%CI, 5.6-9.7) to 35.5 (95%CI, 24.6-52.2). The combination of the four symptoms
showed an AUC of 0.810 (95%CI 0.795-0.825) in classifying NPS-P, and was applied to the non-hospitalized and non-tested
sample (n=165,782). We found that from 4.4% to 12.1% of respondents had experienced symptoms suggestive of COVID-19
infection.
Conclusions: Our results suggest that self-reported symptoms may be reliable indicators of SARS-CoV-2 infection in a
pandemic context. A not negligible part (up to 12.1%) of the symptomatic respondents were left undiagnosed and potentially
contributed to the spread of the infection.
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ABSTRACT
Background
Understanding the occurrence of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-
2)-like symptoms in a large non-hospitalized population, when the epidemic peak was occurring in
Italy, is of paramount importance but data are scarce. 
Objective
Aims of this study were to evaluate the association of self-reported symptoms with SARS-CoV-2
nasopharyngeal swab (NPS) test in non-hospitalized individuals and to estimate the occurrence of
COVID-19-like symptoms in a larger non-tested population.
Methods
This  is  an  Italian  countrywide  self-administered  cross-sectional  web-based  survey  on  voluntary
adults who completed an anonymous questionnaire in the period 13-21 April 2020. The associations
between symptoms potentially related to SARS-CoV-2 infection and NPS results were calculated as
adjusted odds ratios with 95% confidence intervals (aOR, 95%CI) by means of multiple logistic
regression  analysis  controlling  for  age,  sex,  education,  smoking  habits,  and  the  number  of  co-
morbidities.  Thereafter,  for  each  symptom and  for  their  combination,  we  calculated  sensitivity,
specificity,  accuracy and AUC in a  ROC analysis  to  estimate the occurrence of  COVID-19-like
infections in the non-tested population. 
Results
A total of 171,310 responded to the survey (59.9% females, mean age 47.4 years). Out of the 4,785
respondents with known NPS test result, 4,392 were not hospitalized. Among them, the NPS positive
respondents  (n=856)  most  frequently  reported  myalgia  (61.6%),  olfactory  and/or  taste  disorders
(OTDs,  59.2%),  cough (54.4%),  and fever  (51.9%) whereas  7.7% were  asymptomatic.  Multiple
regression analysis showed that OTDs (aOR 10.3, [95%CI 8.4-12.7]), fever (2.5, 95%CI 2.0-3.1),
myalgia (1.5, 95%CI 1.2-1.8), and cough (1.3, 95%CI 1.0-1.6) were associated with NPS positivity.
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Having two to four of these symptoms increased the aOR from 7.4 (95%CI, 5.6-9.7) to 35.5 (95%CI,
24.6-52.2). The combination of the four symptoms showed an AUC of 0.810 (95%CI 0.795-0.825) in
classifying NPS-P, and was applied to the non-hospitalized and non-tested sample (n=165,782). We
found that from 4.4% to 12.1% of respondents had experienced symptoms suggestive of COVID-19
infection.
Conclusions
Our results suggest that self-reported symptoms may be reliable indicators of SARS-CoV-2 infection
in a pandemic context. A not negligible part (up to 12.1%) of the symptomatic respondents were left
undiagnosed and potentially contributed to the spread of the infection.  
Key  words:  SARS-CoV-2; COVID-19,  voluntary  respondents;  web-based  survey;  self-reported
symptoms; nasopharyngeal swab testing
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INTRODUCTION
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that started in late
December 2019 in the Hubei province of China caused millions of cases worldwide in just a few
months, and evolved into a real pandemic[1,2]. As of June 25th, 2020, there were 239,706 confirmed
cases and 34,678 reported deaths in Italy[3]. 
It is worth noting that only approximately 20% of SARS-CoV-2 infected patients required hospital
care[4]. The vast majority experience mild or subclinical form of the disease did not require hospital
admission[5] and a relatively high percentage (40 to 45%) remained asymptomatic[6]. 
Fever, upper respiratory symptoms, myalgia, headache, and gastrointestinal disturbances have been
frequently  reported[4,7],  as  well  as  the  olfactory  and  taste  disorders  (OTDs),  by  SARS-CoV-2
patients[8]. Nevertheless, the prevalence of COVID-19 related symptoms in the population of non-
hospitalized is still poorly investigated[9,10]. An early recognition of the conditions attributable to
the infection is of paramount importance. This is particularly relevant for identifying promptly not
only cases with severe clinical course but also the ones with milder symptomatology who can spread
the  infection,  and who need to  be  immediately  quarantined while  testing  and contact  tracing  is
carried out.
This study is based on EPICOVID19, an anonymised self-administered web-based survey aimed at
estimating the number of suspected cases of COVID-19 and investigating the role of the potential
determinants of SARS-CoV-2 infection in a large Italian sample of respondents living in Italy during
the  lockdown  (started  in  Italy  on  9  March  2020).  The  aims  of  this  paper  are  to  evaluate  the
association of self-symptoms with SARS-CoV-2 nasopharyngeal swab (NPS) test in non-hospitalized
individuals,  and  to  estimate  the  occurrence  of  COVID-19-like  symptoms  in  the  non-tested
population.    
METHODS
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Study design and setting
EPICOVID19 is a national Italian internet-based survey that was carried out using a cross-sectional
research design by a working group dedicated to collaborative public health SARS-CoV-2 research.
The survey was launched on 13 April 2020 and targeted adult volunteers living in Italy during the
lockdown. 
Recruitment
In  order  to  enrol  as  many  subjects  as  possible,  the  survey  was  promoted  using  social  media
(Facebook, Twitter, Instagram, Whatsapp), press releases, internet pages, local radio and TV stations,
and institutional websites that called upon volunteers to contact the study website[11]. The inclusion
criteria were i) age of  >18 years; ii) access to a mobile phone, computer, or tablet with internet
connectivity; and iii) on-line consent to participate in the study. 
Development of the web-based questionnaire
EPICOVID19 was developed by the working group after a literature review of existing research into
COVID-19, starting with the WHO protocols[12],  and of the standard and validated instruments
previously  used  to  investigate  severe  acute  respiratory  syndrome  (SARS)  and  Middle  Eastern
respiratory syndrome (MERS)[13,14].
The  questionnaire  was  adapted  to  the  national  context  and  implemented  using  the  European
Commission's open-source official EUSurvey management tool[15]. The participants were asked to
complete the self-administered 38-item questionnaire, which contained mainly mandatory and closed
questions divided into six sections: i) socio-demographic data; ii) clinical evaluation; iii) personal
characteristics and health status; iv) housing conditions; v) lifestyle; and vi) behaviours following the
lockdown (see Annex 1).
Data collection and variables
For the purposes of this study, we analysed a sub-set of data collected between 13 and 21 April 2020.
The socio-demographic information included sex (male vs female), age (18-30, 30-39, 40-49, 50-59,
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60-69, 70-79, and 80+ years), educational level (primary school or less, middle or high school, and
university degree or post-graduate), and occupational status (unemployed, employed, retired, student,
and other). Smoking habits were classified as never, former and current smoking. A new variable was
created by summing  the chronic conditions referred by participants, including lung diseases, heart
diseases, hypertension, kidney diseases, immune system diseases, tumours, metabolic diseases, liver
diseases, and depression and/or anxiety (categorised as none, 1, 2 or >3 co-morbidities). The SARS-
CoV-2 related symptoms included: fever of >37.5° for at least three consecutive days; headache,
chest pain, myalgia, OTDs, shortness of breath, and feelings of having a fast-beating; gastrointestinal
disturbances, including nausea, vomiting and diarrhoea; conjunctivitis; sore throat, rhinorrhoea, and
cough  (all  dichotomised  as  present/absent).  The  month  of  onset  of  the  first  symptoms
(February/March/April 2020), results of NPS tests (categorised as not done, done with a negative
result,  done  with  a  positive  result,  and  done  with  an  unknown  result),  and  hospitalisation  for
confirmed or suspected SARS-CoV-2 infection (dichotomised as yes/no) were also collected. 
Study groups definitions
For the aims of this study, we defined three study samples: 
1. Sample A, including the total population of respondents (N=171,310); 
2. Subsample B, including the non-hospitalized individuals and NPS tested with known result
(n=4,392); 
3. Subsample C, including the non-hospitalized and non-tested individuals (n=165,782). 
Statistical analysis
The continuous variables were expressed as mean values with standard deviations (SD), and the
categorical  variables  as  counts  and  percentages.  The  χ2 test  and  one-way  analysis  of  variance
(ANOVA) were used to compare the characteristics of respondents by NPS test result (sample A).
The geographical coverage of the sample was evaluated by calculating response rates by Italian
region  standardized  by  the  number  of  residents  aged  >18  years  on  1  January  2019[16].  When
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analysing subsample B we calculated the matrix of pairwise tetrachoric correlations of self-reported
symptoms, given the dichotomous nature of these variables. Crude and adjusted logistic regression
models, controlling for age, sex, education, smoking habits, and the number of co-morbidities were
applied to assess the measurements of association between self-reported symptoms and SARS-CoV-2
NPS positivity versus negativity by estimating the odds ratios (aOR) and 95% Confidence Intervals
(CI).  Subsequently, a numerical variable including all of those symptoms significantly associated
with NPS positivity was created and included in the logistic regression model instead of the single
symptoms.  Age-  and  sex-stratified  analyses  were  also  performed.  In  a  sensitivity  analysis  we
excluded the respondents who reported February as the month of symptom onset in order to avoid
the possible confounding by influenza-like illness (the peak of the Italian flu season 2019-2020 was
from January 27th to February 2nd)[17]. Finally, after assessing sensitivity (Se), specificity (Sp) and
the Area Under Curve (AUC) in a Receiver Operating Characteristic (ROC) analysis, the symptoms
significantly  associated  with  NPS-P were  combined  as  a  proxy  of  COVID-19-like  infection  in
subsample C. All of the statistical analyses were carried out using SPSS Statistics software version
25 (IBM Corp., Armonk, NY, USA) and STATA version 15.0 (StataCorp LP., College Station, Texas,
USA). Two-tailed P-values < .05 were considered statistically significant. 
Ethics and consent form
The  Ethics  Committee  of  the  Istituto  Nazionale  per  le  Malattie  Infettive  I.R.C.C.S.  Lazzaro
Spallanzani (Protocol No. 70, 12/4/2020) approved the EPICOVID19 study protocol. When they first
accessed the on-line platform, the participants were informed of the purpose of the study, the data to
be collected, and the methods of storage and filled in the informed consent. The planning conduct
and reporting of studies was in line with the Declaration of Helsinki, as revised in 2013. Data were
handled and stored in accordance with the European Union General Data Protection Regulation (EU
GDPR)  2016/679,  and  data  transfer  was  safeguarded  by  means  of  encrypting/decrypting  and
password protection. 
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RESULTS 
Characteristics of the respondents
Table  1 summarises  the  characteristics  of  the  171,310  respondents  who  completed  the  survey
between 13 and 21 April 2020 (sample A). They were prevalently female (59.9%); the mean age of
the females was 46.8 (SD, 14.2) years and that of the males was 48.2 (SD, 15.0) years, sixty-one
percent had a university degree or post-graduate qualification, and most were regularly employed
(69.8%).  Smokers and ex-smokers accounted for 42.5% of the respondents (40.0% of the females
and 46.5% of the males). About two-thirds of the respondents had no chronic condition, and the vast
majority (96.9%) did not undergo NPS testing for SARS-CoV-2. Of the 5,317 who did, 1,135 tested
positive (NPS-P), 3,650 tested negative (NPS-N), and 532 did not have the result at the time of
completing the questionnaire. A total of 170,700 respondents were non-hospitalized. 
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Table 1. Characteristics of the respondents by sex (N=171,310, sample A)
Sex at birth
Females Males Total
n % n % n %
Age class, years
18-30 13,538 13.2 8,611 12.5 22,149 12.9
30-39 21,002 20.5 13,351 19.4 34,353 20.1
40-49 22,907 22.3 14,412 21.0 37,319 21.8
50-59 23,815 23.2 14,941 21.7 38,756 22.6
60-69 16,088 15.7 11,710 17.0 27,798 16.2
70-79 4,386 4.3 4,938 7.2 9,324 5.4
80+ 807 0.8 804 1.2 1,611 0.9
             Age in years, mean SD 46.8 14.2 48.2 15.0 47.4 14.5
Education
Primary school or less 5,036 4.9 4,005 5.8 9,041 5.3
Middle or high school 33,049 32.2 24,637 35.8 57,686 33.7
University degree or post-graduate 64,458 62.9 40,125 58.3 104,583 61.0
Occupational status
Unemployed 5,632 5.5 2,136 3.1 7,768 4.5
Employed 70,577 68.8 49,008 71.3 119,585 69.8
Retired 12,281 12.0 10,594 15.4 22,875 13.4
Student 7,196 7.0 4,757 6.9 11,953 7.0
Other 6,857 6.7 2,272 3.3 9,129 5.3
Smoking habit
Never smokers 61,594 60.1 36,787 53.5 98,381 57.4
Former smokers 22,017 21.5 18,986 27.6 41,003 23.9
Current smokers 18,932 18.5 12,994 18.9 31,926 18.6
Number of co-morbidities
None 66,294 64.6 44,887 65.3 111,181 64.9
One 27,016 26.3 17,562 25.5 44,578 26.0
Two 7,099 6.9 4,841 7.0 11,940 7.0
Three or more 2,134 2.1 1,477 2.1 3,611 2.1
Molecular test for SARS-CoV-2
Not done 99,084 96.6 66,909 97.3 165,993 96.9
Done, with a negative result 2,440 2.4 1,210 1.8 3,650 2.1
Done, with a positive result 668 0.7 467 0.7 1,135 0.7
Done, with unknown result 351 0.3 181 0.3 532 0.3
Hospitalized for suspected/confirmed SARS-CoV-2 infection 328 0.3 282 0.4 610 0.4
Not hospitalized, with known molecular test result 2,931 2.9 1,461 2.1 4,392 2.6
All 102,543 59.9a 68,767 40.1a 171,310 100a
aRow percentage 
If unspecified, percentages are column%.
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Six hundred and ten respondents (0.35%) said that they had been hospitalised between 1 February
and 21 April 2020, including 399 of the 5,317 who were tested for SARS-CoV-2 infection (7.5%)
(Supplementary Table S1). Females and younger respondents were less likely to be NPS-P, whereas
those with a lower level of education or retired were more frequently NPS-P.  Current smokers were
less prevalent among the subjects with a positive NPS test (9.5%). 
Geographical coverage 
Although  it  lacked  a  formal  sampling  strategy,  the  survey  reached  a  large  number  of  subjects
throughout Italy. Figure 1 shows the standardized response rates and the incidence of SARS-CoV-2
infection per 100,000 inhabitants by Italian region as of 23 April 2020[16,18]. As expected, response
rates were higher in the northern regions (Lombardy and Piedmont) and reflected the incidence of
confirmed cases at that time.
Self-reported symptoms
Figure  2 shows  that  68,337  respondents  (39.9%)  indicated  no  symptoms.  The  most  frequently
reported  symptoms  were  sore  throat/rhinorrea  (32.9%),  headache  (27.7%),  myalgia  (19.2%),
gastrointestinal  disturbances  (16.5%),  conjunctivitis  (9.3%),  and  fever  (8.0%)  (sample  A).  The
absence of symptoms was less frequent among the NPS-P than the NPS-N respondents (6.2%  vs
30.1%), and there were also notable between-groups differences in the frequency of fever (61.0% vs
16.4%), OTDs (58.5%  vs 8.7%), myalgia (60.8%  vs 27.8%), cough (57.5%  vs 28.7%), headache
(53.8%  vs 34.7%)  and  gastrointestinal  symptoms  (44.8%  vs 23.6%).  In  102,973  symptomatic
subjects, the mean number of symptoms was 5.05 among NPS-P, 3.55 among those with unknown
results,  3.16  among  NPS-N,  and  2.57  among  subjects  who  did  not  perform the  molecular  test
(P<.001). 
In the tetrachoric correlation analysis between symptoms (Supplementary Table S2) performed in
subsample  B,  values  >.6  of  the  correlation  coefficient  resulted  in  the  subgroup  of  symptoms
including  fever,  OTDs,  cough  and  myalgia,  whilst  values  <.3  were  mainly  observed  for  sore
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throat/rinhorrea and conjunctivitis. In the same subsample B, from univariate and multiple logistic
regression  analysis  controlling  for  sex,  age,  education,  smoking  habits  and  the  number  of
comorbidities, all of the considered symptoms resulted positively associated with NPS-P (Table 2).
In the final multiple regression model,  with all symptoms included, OTDs (aOR 10.32, [95%CI,
8.39-12.70]), fever (2.46, 95%CI, 1.98-3.05), myalgia (1.45, 95%CI, 1.17-1.80) and cough (1.28,
95%CI, 1.03-1.58) resulted significantly associated with NPS-P. Age per each additional year (1.02,
95%CI, 1.01-1.03) and male sex (1.34, 95%CI, 1.11-1.63) also had increased odds of a positive test,
whereas current smoking (0.66,  95%CI,  0.50-0.87)  was associated with decreased odds (data not
shown). After adding the composite variable of fever, myalgia, cough and OTD to the model and
simultaneously  adjusting  for  the  other  symptoms,  we  found  a  strong  positive  and  statistically
significant association. The corresponding aORs for the presence of one, two, three and four of these
symptoms  were  respectively  2.66  (95%CI,  2.03-3.49),  7.35  (95%CI,  5.57-9.70),  18.55  (95%CI,
13.77-24.97), and 35.50 (95%CI, 24.60-51.24). 
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Table 2. Odds ratios of positive molecular test in non-hospitalized respondents with known molecular test results (n=4,392, subsample B)
Negative Positive Model 1 Model 2 Model 3
n=3,536 pct=80.5a n=856 pct=19.5a OR (95% CI)1 aOR (95% CI)2 aOR (95% CI)3 P-value
Fever 518 14.6 444 51.9 6,28 (5,33-7,39) 6,08 (5,15-7,17) 2.46 (1.98-3.05) <.001
Myalgia 961 27.2 527 61.6 4,29 (3,67-5,02) 4,33 (3,69-5,07) 1.45 (1.17-1.80) .001
Olfactory and/or taste disorders 291 8.2 507 59.2 16,20 (13,51-19,42) 16,98 (14,07-20,48) 10.32 (8.39-12.70) <.001
Cough 984 27.8 466 54.4 3,10 (2,66-3,61) 3,09 (2,65-3,61) 1.28 (1.03-1.58) .02
Shortness of breath 335 9.5 182 21.3 2,58 (2,12-3,15) 2,63 (2,15-3,23) 0.89 (0.67-1.18) .40
Chest pain 386 10.9 206 24.1 2,59 (2,14-3,12) 2,61 (2,15-3,16) 0.92 (0.70-1.20) .54
Feelings of having a fast-beating 354 10.0 165 19.3 2,15 (1,75-2,63) 2,21 (1,80-2,72) 0.93 (0.70-1.23) .61
Gastrointestinal disturbances 817 23.1 382 44.6 2,68 (2,30-3,13) 2,82 (2,40-3,30) 1.20 (0.98-1.48) .08
Conjunctivitis 351 9.9 156 18.2 2,02 (1,65-2,48) 2,07 (1,68-2,55) 1.11 (0.85-1.45) .45
Sore throat/rhinorrea 1,332 37.7 415 48.5 1,56 (1,34-1,81) 1,64 (1,40-1,91) 0.87 (0.71-1.07) .18
Headache 1,213 34.3 485 56.7 2,50 (2,15-2,91) 2,64 (2,26-3,09) 1.18 (0.95-1.45) .13
Number of symptomsb
None 1,931 54.6 118 13.8 1 1 1
One 854 24.1 133 15.5 2,55 (1,96-3,31) 2,61 (2,01-3,39) 2.66 (2.03-3.49) <.001
Two 441 12.5 185 21.6 6,86 (5,33-8,84) 7,06 (5,47-9,12) 7.35 (5.57-9.70) <.001
Three 222 6.3 239 27.9 17,62 (13,58-22,86) 17,86 (13,71-23,27) 18.55 (13.77-24.97) <.001
All 88 2.5 181 21.1 33,66 (24,56-46,14) 34,02 (24,71-46,85) 35.50 (24.60-51.24) <.001
a Row percentage 
b Ordinal variable summing up the presence of fever, myalgia, cough and olfactory and/or taste disorders 
1 Crude Odd Ratios
2 Controlling for sex, age, education, smoking habit, and number of co-morbidities
3 Controlling for sex, age, education, smoking habit, and number of co-morbidities; including all symptoms
If unspecified, percentages are column%. P-values refer to model 3
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Excluding  the  respondents  who  referred  that  their  first  symptom  appeared  in  February  in  the
sensitivity analysis did not substantially change the results (Supplementary Table S3). 
In Tables 3 and 4 are shown the results of the sex- and age-stratified multiple regression analyses.
OTDs were more closely associated with the odds of a positive test in females (12.10, 95%CI, 9.35-
15.67)  and  subjects  aged  <50  (15.88,  95% CI,  12.10-20.84),  whereas  fever  was  more  closely
associated with NPS-P in males (3.90, 95%CI, 2.72-5.59) and subjects aged  >50 (3.46, 95%CI,
2.50-4.78).
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Table 3. Sex-specific adjusted odds ratiosa of positive molecular test in non-hospitalized respondents with known molecular test results
(n=4,392, subsample B)
Females Males
n=2,931, pct=66.7b n=1,461, pct=(33.3)b
Negative Positive Negative Positive
n=2,376 pct=81.1b n=555 pct=18.9b aOR (95% CI) P-value n=1,160 pct=79.4b n=301 pct=20.6b aOR (95% CI) P-value
Fever 341 14.4 272 49.0 1.87 (1.42-2.46) <.001 177 15.3 172 57.1 3.90 (2.72-5.59) <.001
Myalgia 674 28.4 352 63.4 1.42 (1.08-1.87) .01 287 24.7 175 58.1 1.42 (0.99-2.06) .06
Olfactory and/or taste disorders 210 8.8 357 64.3 12.10 (9.35-15.67) <.001 81 7.0 150 49.8 8.58 (5.92-12.43) <.001
Cough 667 28.1 306 55.1 1.34 (1.03-1.74) .03 317 27.3 160 53.2 1.13 (0.79-1.62) .50
Shortness of breath 239 10.1 131 23.6 0.88 (0.63-1.23) .45 96 8.3 51 16.9 0.91 (0.54-1.55) .74
Chest pain 276 11.6 154 27.7 1.04 (0.76-1.44) .79 110 9.5 52 17.3 0.72 (0.43-1.18) .19
Feelings of having a fast-beating 279 11.7 129 23.2 0.91 (0.66-1.27) .60 75 6.5 36 12.0 1.10 (0.62-1.94) .75
Gastrointestinal disturbances 587 24.7 266 47.9 1.14 (0.88-1.48) .34 230 19.8 116 38.5 1.34 (0.94-1.92) .11
Conjunctivitis 244 10.3 112 20.2 1.19 (0.86-1.64) .29 107 9.2 44 14.6 1.00 (0.61-1.63) .99
Sore throat/rhinorrea 950 40.0 279 50.3 0.77 (0.60-0.99) .04 382 32.9 136 45.2 1.06 (0.75-1.49) .76
Headache 900 37.9 338 60.9 1.09 (0.84-1.42) .50 313 27.0 147 48.8 1.33 (0.93-1.90) .11
Number of symptomsc
None 1,288 54.2 73 13.2 1 643 55.4 45 15.0 1
One 566 23.8 85 15.3 2.81 (2.00-3.96) <.001 288 24.8 48 15.9 2.39 (1.53-3.72) <.001
Two 306 12.9 112 20.2 7.13 (5.00-10.16) <.001 135 11.6 73 24.3 7.95 (5.06-12.47) <.001
Three 150 6.3 162 29.2 20.35 (14.00-29.57) <.001 72 6.2 77 25.6 15.30 (9.29-25.22) <.001
All 66 2.8 123 22.2 35.28 (22.44-55.47) <.001 22 1.9 58 19.3 39.65 (20.69-76.00) <.001
aAfter controlling for sex, age, education, smoking habit, and number of co-morbidities
bRow percentage 
cOrdinal variable summing up the presence of fever, myalgia, cough and olfactory and/or taste disorders 
If unspecified, percentages are column%.
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Table 4. Age-specific adjusted odds ratiosa of positive molecular test in non-hospitalized respondents with known molecular test results
(n=4,392, subsample B)
Age <50 Age ≥50
n=2,659, pct=60.5b n=1,733, pct=39.5b
Negative Positive Negative Positive 
n=2,176 pct=81.8
b
n=483 pct=18.2
b
aOR (95% CI) P-
value
n=1,36
0
pct=78.5
b
n=37
3
pct=21.5
b
aOR (95% CI) P-
value
Fever 341 15.7 239 49.5 1.98 (1.47-2.65) <.001 177 13.0 205 55.0 3.46 (2.50-4.78) <.001
Myalgia 599 27.5 308 63.8 1.61 (1.20-2.18) .002 362 26.6 219 58.7 1.35 (0.98-1.86) .07
Olfactory and/or taste disorders 177 8.1 323 66.9 15.88 (12.10-20.84) <.001 114 8.4 184 49.3 5.25 (3.75-7.34) <.001
Cough 639 29.4 266 55.1 1.14 (0.85-1.53) .37 345 25.4 200 53.6 1.39 (1.02-1.91) .04
Shortness of breath 223 10.2 117 24.2 0.90 (0.62-1.31) .58 112 8.2 65 17.4 0.79 (0.51-1.23) .29
Chest pain 267 12.3 133 27.5 0.95 (0.67-1.35) .76 119 8.8 73 19.6 0.90 (0.59-1.38) .63
Feelings of having a fast-beating 243 11.2 101 20.9 0.80 (0.55-1.17) .25 111 8.2 64 17.2 1.12 (0.73-1.73) .60
Gastrointestinal disturbances 543 25.0 231 47.8 1.33 (1.00-1.76) .048 274 20.1 151 40.5 1.14 (0.83-1.57) .42
Conjunctivitis 198 9.1 80 16.6 0.93 (0.64-1.36) .71 153 11.3 76 20.4 1.34 (0.92-1.97) .13
Sore throat/rhinorrea 918 42.2 272 56.3 0.89 (0.68-1.17) .41 414 30.4 143 38.3 0.85 (0.63-1.16) .31
Headache 837 38.5 300 62.1 1.23 (0.92-1.63) .16 376 27.6 185 49.6 1.21 (0.88-1.65) .24
Number of symptomsc
None 1,167 53.6 52 10.8 1 764 56.2 66 17.7 1
One 521 23.9 80 16.6 3.70 (2.54-5.41) <.001 333 24.5 53 14.2 1.83 (1.23-2.73) .003
Two 285 13.1 101 20.9 8.91 (6.03-13.15) <.001 156 11.5 84 22.5 6.20 (4.14-9.30) <.001
Three 147 6.8 146 30.2 24.39 (16.19-36.75) <.001 75 5.5 93 24.9 13.98 (8.92-21.90) <.001
All 56 2.6 104 21.5 45.86 (27.94-75.29) <.001 32 2.4 77 20.6 26.27 (14.95-
46.17)
<.001
aAfter controlling for sex, age, education, smoking habit, and number of co-morbidities
bRow percentage 
cOrdinal variable summing up the presence of fever, myalgia, cough and olfactory and/or taste disorders 
If unspecified, percentages are column%.
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After dichotomizing for the presence of two or more and of three or more, the resulting aORs were
12.17  (95%CI,  9.50-15.59)  and  22.44  (95%CI,  16.93-29.75).  When  the  four  symptoms  were
singularly  analyzed,  the  larger  AUC  (0.749,  95%CI  0.730-0.767)  was  found  for  OTDs,
characterized also by better Sp=91.8%, with myalgia having the higher sensitivity (Se=61.6%) in
classifying NPS-P. The combination of the four symptoms increased the AUC to 0.810 (95%CI
0.795-0.825), with higher sensitivity at the cut-off of two or more (Se=70.7) and higher specificity
at the cut-off of three or more (Sp=91.2%) (data not shown).
As  a  final  step,  we  quantified  the  amount  of  probable  SARS-CoV-2  infections  in  the  non-
hospitalized  and  non-tested  population  (subsample  C)  by  calculating  the  frequencies  for  the
combination of the four symptoms resulted from the analysis on subsample B. We found that, with
an accuracy of 77.2% and 83.0% respectively, 20,103 respondents (12.1%, 95%CI 12.0%-12.3%)
had two or more and 7,739 ones (4.4%, 95%CI 4.3%-4.6%) had three or more symptoms suggestive
of novel coronavirus disease.
DISCUSSION
This  study,  based  on  the  responses  of  >170,000  persons  to  a  web-based  survey,  outlined  the
COVID-19 symptom profile of the cases that did not require hospitalisation during the outbreak of
the epidemic in Italy. OTDs, myalgia, fever and cough were symptoms associated with laboratory-
proven SARS-CoV-2 infection. Among non-hospitalized and non-tested respondents, from 4.4% to
12.1% experienced symptoms suggestive of COVID-19 illness.
Although approximately 60% of the respondents reported at least one symptom compatible with the
viral infection, only 3.4% of these had access to NPS testing for SARS-CoV-2. Respondents with at
least one symptom accounted for 94% of NPS-P patients, 70% of NPS-N patients, and 75% of the
patients with an unknown NPS test result. We here report that sub-groups with symptomatology
similar to NPS-P subjects have not been tested, a worrying finding that suggests a large number of
cases may have remained undiagnosed or may not have been correctly quarantined[19]. Active case
finding with prompt isolation and contact tracing would be a highly important means of ending the
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spread  of  SARS-CoV-2  infection[20],  which  otherwise  likely  might  continue  through
households[21]. The very limited number of respondents who were diagnosed based on NPS testing
is a consequence of the decision by health authorities to reserve the use of diagnostics for clinically
severe cases and creating suboptimal conditions for effective contact tracing. 
A number of papers have described the clinical characteristics, symptoms and disease course of
SARS-CoV-2  in-patients[22,23]  and  out-patients[24],  but  still  little  is  known about  the  natural
history of the infection and its clinical spectrum or rate of symptoms in non-hospitalized COVID-19
cases. In our analyses, we showed a strong association between OTDs and NPS-P, with NSP-P
respondents having more than 10-fold increased risk of having OTDs. In line with our findings,
OTDs has been reported as symptom specific of SARS-CoV-2 infection in clinical[8,25] and non-
clinical setting[9,26,27]. In 18,401 users of “COVID symptom tracker mobile app” in UK and US
who underwent molecular testing, loss of smell in addition to fever and persistent cough was found
as potential predictor of COVID-19[9]. Similar results were recently reported from two other on-
line  surveys  in  Italian[26] and in  French  population[27].  Consistently  with  the  aforementioned
population studies,  we also found that other COVID-19 related symptoms as fever,  myalgia or
cough were significantly associated with NPS-P, even though less specific than OTDs. Overall, the
four above-mentioned symptoms demonstrated an additive effect that increases the probability of
NPS-P. 
Interestingly, our sub-set analyses revealed some associations between the respondents’ symptoms
and their demographic characteristics. The association between OTDs and NPS-P was stronger in
younger patients, possibly because the known deterioration in the sense of smell during aging[28]
means that younger subjects are more likely to notice its loss. We also found that NSP-P was more
closely  associated  with  OTDs in  women  and  with  fever  in  men,  although  both  symptoms are
significantly associated with NSP-P in both sexes. The association between female and OTDs has
also been reported in hospitalized COVID-19 patients[8]. 
Notably,  in  the  subpopulation  of  165,782  participants  who  were  not  NPS-tested  and  non-
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hospitalized,  we calculated  with  accuracy  close  to  80% that  12.1% had two or  more  of  these
symptoms and 4.4% had three or more, leading to a significant number of adults with COVID-19-
like illness. Applying the most conservative criterion (presence of three or more symptoms at the
same time), characterized by a specificity of 91.2%, we estimated that about 2.2 millions of Italian
adults had high probability of being COVID-19 symptomatic cases up to April 21, 2020.  
The estimation of the real proportion of the population infected is a fundamental indicator for public
health policy makers in the ongoing COVID-19 pandemic.  During the epidemic peak, model-based
estimates[29] have suggested that the ratio between notified and actual cases ranges from 1:5 to
1:20, but to date in Italy real-world data are limited to restricted local settings or are available only
in case of NPS testing of symptomatic patients with serious illness and requiring intensive or sub-
intensive  medical  care.  This  lack  has  led  to  a  wide  underestimation  of  the  spread  of  novel
coronavirus in the mild symptomatic individuals or in those with limited access to testing. For this
reason,  our  results  seem  to  be  quite  and  consistent  with  other  surveys  performed  in  large
populations.  A model  combing symptoms to predict  probable infection was applied to  the data
derived from the “COVID symptom tracker mobile app” in UK and USA[9], indicating that the
17.4% users were likely to have COVID-19-like infection. Data from a nationally representative
survey of Canadian indicated that about 8% of adults reported  they or someone in their household
had symptoms suggestive of novel coronavirus disease in March 2020[10]. 
These  findings  suggest  that  during  a  pandemic,  when  testing  and  contact  tracing  should  be
prioritized,  the  presence  of  such  symptoms,  also  detected  through  a  simple  anamnestic
investigation, may be an early indicator of SARS-CoV-2 infection in individuals who should be
quarantined and molecularly tested. 
It is also interesting to note that 7.7% of non-hospitalized patients with a NPS-P test reported no
symptoms.  A  number  of  studies  have  suggested  that  asymptomatic  patients  may  be  virus
spreaders[30,31]. According to the results from sixteen SARS-CoV-2 testing studies pooled by Oran
and colleagues,  asymptomatic  persons accounted for approximately 40% to 45% of COVID-19
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infections[6]. In the Italian population study carried out on about 2,500 residents in the municipality
of Vo’, authors showed that the age-adjusted prevalence of COVID-19 asymptomatic cases was
43.2% (95CI 32.2%-54.7%)[5]. The characteristics of our study make it unsuitable for precisely
estimating the percentage of completely asymptomatic, and our lower-than-expected findings can
be explained by the limited access to molecular testing for the asymptomatic individuals and by the
possible over-reporting of symptoms. 
Our  data  concerning  an  apparently  protective  role  of  smoking  in  relation  to  NPS-P add  new
evidence to a panorama in which it has been suggested that this habit may have divergent clinical,
prognostic and epidemiological effects in COVID-19 patients[32]. This issue will be investigated in
more detail in a separate article in order to contribute further to the current debate[33].
Study limitations and strengths
Given the voluntary nature of the survey, it was not intended to assess a representative sample of the
general population. However, extensive participation has allowed us to collect a sample that is quite
balanced in terms of gender and age, although more shifted towards younger subjects with a higher
level of education as can be expected in the case of an on-line questionnaire. The characteristics of a
web-based survey may have also introduced a bias leading people with symptoms to respond more
often  than  those  without  symptoms,  and people  who are  health-conscious  to  exacerbate  (over-
report) their symptoms. In addition, some symptoms (e.g OTDs) are more likely to be subjected to
recall bias due to media emphasis on their association with the disease. 
At the date of the survey collection analysis the NPS “testing rate” among Italian adults (age≥18
years) was 1.92%[3] versus 3.10% among responders to EPICOVID19, suggestive of a  greater
propensity to participate for individuals who felt at higher risk, for symptomatology or closeness to
COVID-19 cases. On 21st April the total number of SARS-CoV-2 cases in Italy was 183,957[3] out
of the 971,246 individuals who underwent the NPS test, with a NPS-positive cumulative prevalence
rate equal to 18.9%, similarly to the rate of 23.7% observed in our study. By that time, in Italy the
cumulative number of hospitalized COVID-19 patients was 78,205, and the number of deceased
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due to novel coronavirus (unknown if hospitalized) was 24,648. The cumulative prevalence rate of
hospitalized COVID-19 cases therefore ranged 0.15%-0.20% among the Italian adults. The total
number of hospitalized EPICOVID19 respondents (for suspect or confirmed COVID-19 illness)
was 610 (0.36%), among these 279 (0.16%) were NPS-P, in line with the hospitalization rates in the
general population. 
As the sample was self-selected the generalisability of our results should be done with caution.
Lastly, a single self-reported negative test cannot exclude a possible SARS-CoV-2 infection. 
On-line surveys have become an accepted,  low-cost and scalable means[34,35] of efficiently and
rapidly involving a large number of people regardless of geographical distance, thus making them
somehow preferable to more traditional, time-consuming and expensive methods, especially in an
ongoing emergency situation.  Further,  in the context  of  this  outbreak the EPICOVID19 survey
might have involved people who had no opportunity to report their symptoms in other ways. It is
noteworthy  that  our  survey  achieved  a  satisfactory  geographical  coverage,  proportional,  as
expected,  to  the  distribution  of  COVID-19  infection  and  to  the  reasonable  likelihood  that
communities living in more affected areas would be more willing to respond.
To  the  best  of  our  knowledge,  this  is  the  largest  Italian  web-based  survey  of  SARS-CoV-2
symptoms and, notably, carried out during the epidemic peak in Italy, when data at population level
were unavailable. National authorities, healthcare workers and the public have known little about
the  real  spread  of  the  infection  since  it  started.  Our  preliminary  findings  shed  some  light  on
paucisymptomatic or mild infections by novel coronavirus disease in Italy.
Conclusions 
The  adoption  of  effective  strategies  and  ready-to-use  digital  tools,  like  the  real-time  reporting
internet-based EPICOVID19, aimed at ascertaining the positivity of paucisymptomatic carriers is
still urgently needed in Italy and worldwide. The implementation of these strategies is fundamental
also in countries, like the European ones, where the spread of the infection is currently declining but
programs of active surveillance are necessary to reduce the risk of a new SARS-CoV-2 outbreak in
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the future. Many individuals with COVID-like infection are destined to remain beyond the control
of  the  health  authorities,  thus  representing  an  important  source  for  the  further  spread  of  the
infection. The determination of a symptomatic profile capable of easily identifying a suspected case
may  greatly  contribute  to  contain  the  pandemic.  Although  they  are  also  associated  with  other
respiratory tract infections, the simultaneous presence of symptoms such as fever, cough, myalgia
and OTDs revealed by this study seems to be associated with a high probability of carrying active
SARS-CoV-2 infection in a pandemic context. 
https://preprints.jmir.org/preprint/21866 [unpublished, non-peer-reviewed preprint]
JMIR Preprints Adorni et al
Abbreviations
Severe Acute Respiratory Syndrome-Coronavirus-2 - SARS-CoV-2
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Figure 1. Title: Comparison of survey response rates and the incidence of SARS-CoV-2 infection
per 100,000 inhabitants by Italian region.
Legend: Left: response rates x100,000. Right: incidence rates of SARS-CoV-2 x100,000.
Figure 2. Title: Self-reported symptoms in 171,310 respondents by SARS-CoV-2 molecular test.
Legend: Error bars are ±2*standard error (normal approximation).
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Title: Self-reported symptoms in 171,310 respondents by SARS-CoV-2 molecular test. Legend: Error bars are ±2*standard
error (normal approximation).
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Title: Comparison of survey response rates and the incidence of SARS-CoV-2 infection per 100,000 inhabitants by Italian
region. Legend: Left: response rates x100,000. Right: incidence rates of SARS-CoV-2 x100,000.
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